RNAC Key Statistics, Chart & Performance
The current stock price of RNAC is 6.68 USD. In the past month the price decreased by -12.11%. In the past year, price decreased by -66.25%.
RNAC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About RNAC
Company Profile
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Frederick, Maryland and currently employs 66 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Company Info
CARTESIAN THERAPEUTICS INC
7495 New Horizon Way
Frederick MARYLAND US
Employees: 66
Phone: 13013488698
CARTESIAN THERAPEUTICS INC / RNAC FAQ
What does CARTESIAN THERAPEUTICS INC do?
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Frederick, Maryland and currently employs 66 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
What is the current price of RNAC stock?
The current stock price of RNAC is 6.68 USD. The price decreased by -1.18% in the last trading session.
Does CARTESIAN THERAPEUTICS INC pay dividends?
RNAC does not pay a dividend.
How is the ChartMill rating for CARTESIAN THERAPEUTICS INC?
RNAC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of RNAC stock?
CARTESIAN THERAPEUTICS INC (RNAC) operates in the Health Care sector and the Biotechnology industry.
What is the next earnings date for RNAC stock?
CARTESIAN THERAPEUTICS INC (RNAC) will report earnings on 2026-03-11, after the market close.
What is the ownership structure of CARTESIAN THERAPEUTICS INC (RNAC)?
You can find the ownership structure of CARTESIAN THERAPEUTICS INC (RNAC) on the Ownership tab.
RNAC Technical Analysis
RNAC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RNAC. While RNAC seems to be doing ok healthwise, there are quite some concerns on its profitability.
RNAC Financial Highlights
Over the last trailing twelve months RNAC reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS increased by 83.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.58% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RNAC Forecast & Estimates
15 analysts have analysed RNAC and the average price target is 35.99 USD. This implies a price increase of 438.79% is expected in the next year compared to the current price of 6.68.
For the next year, analysts expect an EPS growth of 79.52% and a revenue growth -95.02% for RNAC